NICOLE CARACCIOLI: Open Payments
NPI 1851090013 · DENHAM SPRINGS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,045 in 57 payments from 11 companies in 2025. Trend: 2023 $378 · 2024 $1,112 · 2025 $1,045
Food & beverage: $1,045
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $192 |
| ABBVIE INC. | 10 | $165 |
| Alkermes, Inc. | 11 | $155 |
| Vanda Pharmaceuticals Inc. | 5 | $119 |
| Lundbeck LLC | 5 | $88 |
| Indivior Inc. | 3 | $73 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Neurocrine BioSciences, Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $45 |
Products named: REXULTI, ARISTADA, VRAYLAR, ABILIFY ASIMTUFII, FANAPT, SUBLOCADE, Auvelity, UZEDY.
Industry payments across LA — which companies pay providers there.
